Board of Directors

Oliver Sexton

Dr Andrew Lightfoot
CEO

Dr Martin Stocks
COO

Oliver Sexton joined Midven in April 2014 to manage the UK Innovation & Science Seed Fund’s synthetic biology investments.

Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.

Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.

Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.

Dr Andrew Lightfoot (CEO) joined Procarta as CEO in 2017. Andrew is a medicinal chemist by background and has 19 years’ experience in leading drug discovery/development in multiple therapeutic areas (antimicrobials, neurosciences and immuno-inflammation) in both large pharma and biotech. From 2011-17, he was founder, CEO and Director of Peptinnovate, a respiratory drug discovery and development company, which he took from early discovery to Phase 1 clinical studies.

At GSK, 1998-2010, he led discovery efforts leading to a number of molecules progressing into clinical trials. He was part of the out-licensing team of a number of assets to Proximagen in 2011. From 2010-11 he was Chief Executive Officer of Helperby Therapeutics where he helped design and execute a phase 2a clinical study for MRSA. From 2012-14, he was an NED of CytaCoat AB, a Swedish antimicrobial coating company. He is a Board member of the BioIndustry Association (BIA).

Dr Martin Stocks (COO) has over 30 years’ experience in research and scientific commercialisation, including in the area of nucleic acid-based biopharmaceuticals.  Founder and CSO of one biotech company (Iclectus Ltd.), he has also managed a specialist CRO (The Model Gut).

He manages the "Health and Medical" portfolio of Plant Bioscience Ltd., a private technology transfer company and is an Investment Executive of the Iceni Seedcorn Fund. Martin has raised close to £12m in VC and translational funding for early-stage ventures/projects, and has negotiated and secured over 50 service or licensing deals including with major pharma (Merck & Co., Novartis, GSK, Pfizer), animal health (Elanco, Ceva), and agbio (Monsanto, Syngenta) companies as well as mid-tier entities and SMEs.